897-C TROCEPT tumor-specific targeting and replication enables in-tumor production of immune checkpoint inhibitors following intravenous delivery

• Andrew B Gerry,
• Bent K Jakobsen,
• David Krige,
• Rahul C Khanolkar,
• James A Davies,
• Alexander T Baker,
• Thomas A Webb,
• Alicia Teijeira-Crespo,
• Hanni K Uusi-Kerttula,
• Lucy M Williams,
• Samantha L Moore,
• Johanne M Pentier,
• Alan L Parker,
• David K Cole

Affiliations

Andrew B Gerry

1Accession Therapeutics Ltd, Oxford, UK

Bent K Jakobsen

1Accession Therapeutics Ltd, Oxford, UK

David Krige

1Accession Therapeutics Ltd, Oxford, UK

Rahul C Khanolkar

1Accession Therapeutics Ltd, Oxford, UK

James A Davies

1Accession Therapeutics Ltd, Oxford, UK

Alexander T Baker

1Accession Therapeutics Ltd, Oxford, UK

Thomas A Webb

1Accession Therapeutics Ltd, Oxford, UK

Alicia Teijeira-Crespo

2Cardiff University, Cardiff, UK

Hanni K Uusi-Kerttula

2Cardiff University, Cardiff, UK

Lucy M Williams

1Accession Therapeutics Ltd, Oxford, UK

Samantha L Moore

1Accession Therapeutics Ltd, Oxford, UK

Johanne M Pentier

1Accession Therapeutics Ltd, Oxford, UK

Alan L Parker

1Accession Therapeutics Ltd, Oxford, UK

David K Cole

1Accession Therapeutics Ltd, Oxford, UK